{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:14:48Z","timestamp":1794014088124,"version":"4.8.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"\n Importance<\/jats:title>\n The randomized clinical trial Cancer and Leukemia Group B (CALGB) 140503 showed that for patients with clinically staged T1N0 non\u2013small cell lung cancer (NSCLC; \u22642 cm), sublobar resections were associated with similar oncological outcomes to those after lobar resection. The association of the extent of parenchymal resection with recurrence and survival in patients with tumors pathologically upstaged to T2 based on visceral pleural invasion (VPI) is controversial.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine survival and recurrence rates in patients with small peripheral pT2 NSCLC (\u22642 cm) that was treated by either lobar or sublobar resection in CALGB 140503.<\/jats:p>\n <\/jats:sec>\n \n Design, Participants, and Setting<\/jats:title>\n CALGB 140503, a randomized multicenter noninferiority trial, included 697 patients with small peripheral NSCLC that was clinically staged as T1N0. Enrollment was from June 2007 through March 2017 at 83 participating institutions, and after a median follow-up of 7 years, the primary outcome of disease-free survival after sublobar resection was noninferior to that after lobar resection.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Lobar or sublobar resection.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Survival end points were estimated by the Kaplan-Meier estimator. Hazard ratios and 95% CIs were estimated using stratified Cox proportional hazard models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 679 participants, 390 (57.4%) were female, and the median (range) age was 67.8 (37.8-89.7) years. Among 697 patients randomized, 566 (81.2%) had pT1 tumors (no VPI) and 113 (16.2%) had pT2 tumors (VPI). Five-year disease-free survival was 65.9% (95% CI, 61.9%-70.2%) in patients with pT1 compared with 53.3% (95% CI, 44.3%-64.1%) in patients with pT2 tumors (stratified log-rank:\n P<\/jats:italic>\n \u2009=\u2009.02). Disease recurrence developed in 27.6% of patients with pT1 (locoregional only: 60 [10.8%]; distant only: 81 [14.6%]) and 41.6% of those with pT2 (locoregional only: 17 [15.0%]; distant only: 27 [23.9%]). Five-year recurrence-free survival was 73.1% (95% CI, 69.2%-77.1%) for pT1 tumors and 58.2% (95% CI, 49.2%-68.8%) for pT2 tumors (stratified log-rank:\n P<\/jats:italic>\n \u2009=\u2009.01). There were no intergroup differences in disease-free or recurrence-free survival based on the extent of parenchymal resection.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The results of this secondary analysis suggest that compared with patients with tumors without VPI, patients who had tumors with VPI had worse disease-free and recurrence-free survival and a higher rate of local and distant disease recurrence. These high rates of recurrence were independent of the extent of parenchymal resection, and these data support the inclusion of these patients in adjuvant therapy trials.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT0049933<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.2491","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T11:48:19Z","timestamp":1722512899000},"page":"1179","source":"Crossref","is-referenced-by-count":38,"title":["Recurrence of Non\u2013Small Cell Lung Cancer With Visceral Pleural Invasion"],"prefix":"10.1001","volume":"10","author":[{"given":"Nasser","family":"Altorki","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine, New York\u2013Presbyterian Hospital, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, and Biostatistics and Bioinformatics, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Damman","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Wigle","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Port","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York\u2013Presbyterian Hospital, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Conti","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et Pneumologie de Qu\u00e9bec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad S.","family":"Ashrafi","sequence":"additional","affiliation":[{"name":"Surrey Memorial Hospital Thoracic Group Fraser Valley Health Authority, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moishe","family":"Liberman","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Landreneau","sequence":"additional","affiliation":[{"name":"Tampa General Hospital, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yasufuku","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Yang","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"University of Colorado Hospital School of Medicine, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Keenan","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bauer","sequence":"additional","affiliation":[{"name":"Hackensack Meridian Health System, Edison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Miller","sequence":"additional","affiliation":[{"name":"Medical College of Georgia, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[{"name":"Alliance Protocol Operations Office, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mentlick","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett","family":"Vokes","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Stinchcombe","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"coi240035r1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1056\/NEJMoa2212083","article-title":"Lobar or sublobar resection for peripheral stage IA non\u2013small-cell lung cancer.","volume":"388","author":"Altorki","year":"2023","journal-title":"N Engl J Med"},{"issue":"10335","key":"coi240035r2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(21)02333-3","article-title":"Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802\/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.","volume":"399","author":"Saji","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"coi240035r3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer.","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"7","key":"coi240035r4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/JTO.0000000000000559","article-title":"The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer.","volume":"10","author":"Rami-Porta","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi240035r5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jtcvs.2004.11.021","article-title":"Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer.","volume":"130","author":"Shimizu","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"coi240035r6","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.athoracsur.2014.11.052","article-title":"Visceral pleural invasion remains a size-independent prognostic factor in stage I non-small cell lung cancer.","volume":"99","author":"Huang","year":"2015","journal-title":"Ann Thorac Surg"},{"issue":"39","key":"coi240035r7","doi-asserted-by":"publisher","first-page":"66576","DOI":"10.18632\/oncotarget.16476","article-title":"Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size = 3cm.","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"coi240035r8","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1378\/chest.13-0394","article-title":"Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma = 2 cm: a proposal to reclassify T1 lung adenocarcinoma.","volume":"144","author":"Nitadori","year":"2013","journal-title":"Chest"},{"issue":"6","key":"coi240035r9","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.athoracsur.2013.03.085","article-title":"Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size.","volume":"95","author":"David","year":"2013","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"coi240035r10","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41598-017-01845-7","article-title":"Extent of visceral pleural invasion affects prognosis of resected non\u2013small cell lung cancer: a meta-analysis.","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"coi240035r11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.athoracsur.2023.06.020","article-title":"Segmentectomy vs lobectomy for early non\u2013small cell lung cancer with visceral pleural invasion.","volume":"117","author":"Mathey-Andrews","year":"2024","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"coi240035r12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.21037\/jtd.2019.12.121","article-title":"Sublobectomy versus lobectomy for long-term survival outcomes of early-stage non-small cell lung cancer with a tumor size =2 cm accompanied by visceral pleural invasion: a SEER population-based study.","volume":"12","author":"Yu","year":"2020","journal-title":"J Thorac Dis"},{"issue":"21","key":"coi240035r13","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi240035r14","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.jtcvs.2016.12.045","article-title":"Biopsy first: lessons learned from Cancer and Leukemia Group B (CALGB) 140503.","volume":"153","author":"Kohman","year":"2017","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2821929\/jamaoncology_altorki_2024_oi_240035_1729098153.72209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:19:37Z","timestamp":1729163977000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2821929"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.2491","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}